Influenza Antiviral Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
MARKET INTRODUCTION
Influenza is a kind of viral infection which has a contagious nature that causes a upper respiratory tract infection and affects nose, throat as well as lungs. The symptoms usually starts from mild nature but can be life threatening it not treated in time. The more prone to infection are the people who have a weakened immune system or having age above 65 years. The symptoms of influenza includes, sweat, chills, sore throat, fever. The major category of drugs which are used in treatment of influenza include, antiviral and immunomodulatory agents.
MARKET DYNAMICS
The key market drivers for Influenza Antiviral Drugs Market Includes, increasing prevalence of influenza infection worldwide along with introduction of novel drug therapies and various treatment options are some factors which will drive market during the forecast period. However, high cost of treatment, expiration of patents and launching of generic drugs are some factors which will hamper market growth during the forecast period.
MARKET SCOPE
The "Influenza Antiviral Drugs Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Influenza Antiviral Drugs market with detailed market segmentation by type, treatment type, mechanism of action, vaccine type, route of administration, and end user. The Influenza Antiviral Drugs Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Influenza Antiviral Drugs Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Influenza Antiviral Drugs Market is segmented on the basis of type, treatment type, mechanism of action, vaccine type, route of administration, and end user. On the basis of type the market is segmented into, influenza, Influenza B, and Influenza C. On the basis of treatment type it is segmented as, medication, chemoprophylaxis and others. On the basis of mechanism of action the market is segmented as, cap- dependent endonuclease inhibitor,nuraminidase inhibitor, matrix-2 protein inhibitor. On the basis of vaccine type quadrivalent, trivalent and others. On the basis of route of administration the market is segmented as, oral, parenteral and others. And on the basis of end user the market is segmented as, hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Influenza Antiviral Drugs Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Influenza Antiviral Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Influenza Antiviral Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Influenza Antiviral Drugs Market in these regions.
Speak to Analyst
MARKET PLAYERS
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Influenza Antiviral Drugs Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Influenza Antiviral Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Influenza Antiviral Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Influenza Antiviral Drugs Market in these regions.
MARKET PLAYERS
The report covers key developments in the Influenza Antiviral Drugs Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Influenza Antiviral Drugs Market are anticipated to have lucrative growth opportunities in the future with the rising demand for Aortic and Peripheral Vascular Interventional Therapy Product, market in the global market. Below mentioned is the list of few companies engaged in the Influenza Antiviral Drugs Market.
The report also includes the profiles of key players in Influenza Antiviral Drugs Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Influenza is a kind of viral infection which has a contagious nature that causes a upper respiratory tract infection and affects nose, throat as well as lungs. The symptoms usually starts from mild nature but can be life threatening it not treated in time. The more prone to infection are the people who have a weakened immune system or having age above 65 years. The symptoms of influenza includes, sweat, chills, sore throat, fever. The major category of drugs which are used in treatment of influenza include, antiviral and immunomodulatory agents.
MARKET DYNAMICS
The key market drivers for Influenza Antiviral Drugs Market Includes, increasing prevalence of influenza infection worldwide along with introduction of novel drug therapies and various treatment options are some factors which will drive market during the forecast period. However, high cost of treatment, expiration of patents and launching of generic drugs are some factors which will hamper market growth during the forecast period.
MARKET SCOPE
The "Influenza Antiviral Drugs Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Influenza Antiviral Drugs market with detailed market segmentation by type, treatment type, mechanism of action, vaccine type, route of administration, and end user. The Influenza Antiviral Drugs Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Influenza Antiviral Drugs Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Influenza Antiviral Drugs Market is segmented on the basis of type, treatment type, mechanism of action, vaccine type, route of administration, and end user. On the basis of type the market is segmented into, influenza, Influenza B, and Influenza C. On the basis of treatment type it is segmented as, medication, chemoprophylaxis and others. On the basis of mechanism of action the market is segmented as, cap- dependent endonuclease inhibitor,nuraminidase inhibitor, matrix-2 protein inhibitor. On the basis of vaccine type quadrivalent, trivalent and others. On the basis of route of administration the market is segmented as, oral, parenteral and others. And on the basis of end user the market is segmented as, hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Influenza Antiviral Drugs Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Influenza Antiviral Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Influenza Antiviral Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Influenza Antiviral Drugs Market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Influenza Antiviral Drugs Market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Influenza Antiviral Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Influenza Antiviral Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Influenza Antiviral Drugs Market in these regions.
MARKET PLAYERS
The report covers key developments in the Influenza Antiviral Drugs Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Influenza Antiviral Drugs Market are anticipated to have lucrative growth opportunities in the future with the rising demand for Aortic and Peripheral Vascular Interventional Therapy Product, market in the global market. Below mentioned is the list of few companies engaged in the Influenza Antiviral Drugs Market.
The report also includes the profiles of key players in Influenza Antiviral Drugs Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- Sun Pharmaceuticals Industries, Ltd
- ADMA Biologics,Inc
- Shionogi Inc
- F. Hoffmann-La Roche Ltd
- Cipla Inc
- Glaxosmithkline Plc
- Teva Pharmaceutical Industries Ltd
- Novartis AG
- Sanofi
- AstraZeneca
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Influenza Antiviral Drugs Market - By Type
1.3.2 Influenza Antiviral Drugs Market - By Treatment Type
1.3.3 Influenza Antiviral Drugs Market - By Mechanism of Action
1.3.4 Influenza Antiviral Drugs Market - By Vaccine Type
1.3.5 Influenza Antiviral Drugs Market - By Routes of Administration
1.3.6 Influenza Antiviral Drugs Market - By End Users
1.3.7 Influenza Antiviral Drugs Market - By Region
1.3.7.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. INFLUENZA ANTIVIRAL DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. INFLUENZA ANTIVIRAL DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. INFLUENZA ANTIVIRAL DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. INFLUENZA ANTIVIRAL DRUGS - GLOBAL MARKET OVERVIEW
6.2. INFLUENZA ANTIVIRAL DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. INFLUENZA A, INFLUENZA B, INFLUENZA C
7.3.1. Overview
7.3.2. Influenza A, Influenza B, Influenza C Market Forecast and Analysis
8. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT TYPE
8.1. OVERVIEW
8.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
8.3. MEDICATION, CHEMOPROPHYLAXIS, OTHERS
8.3.1. Overview
8.3.2. Medication, Chemoprophylaxis, Others Market Forecast and Analysis
9. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - MECHANISM OF ACTION
9.1. OVERVIEW
9.2. MECHANISM OF ACTION MARKET FORECASTS AND ANALYSIS
9.3. CAP- DEPENDENT ENDONUCLEASE INHIBITOR
9.3.1. Overview
9.3.2. Cap- dependent endonuclease inhibitor Market Forecast and Analysis
9.3.3. Daloxavir Market
9.3.3.1. Overview
9.3.3.2. Daloxavir Market Forecast and Analysis
9.4. NURAMINIDASE INHIBITOR
9.4.1. Overview
9.4.2. Nuraminidase Inhibitor Market Forecast and Analysis
9.4.3. Oseltamivir Market
9.4.3.1. Overview
9.4.3.2. Oseltamivir Market Forecast and Analysis
9.4.4. Zanamivir Market
9.4.4.1. Overview
9.4.4.2. Zanamivir Market Forecast and Analysis
9.4.5. Peramivir Market
9.4.5.1. Overview
9.4.5.2. Peramivir Market Forecast and Analysis
9.5. MATRIX-2 PROTEIN INHIBITOR
9.5.1. Overview
9.5.2. Matrix-2 Protein Inhibitor Market Forecast and Analysis
9.5.3. Amantadine Market
9.5.3.1. Overview
9.5.3.2. Amantadine Market Forecast and Analysis
9.6. VIRAL UNCOATINGS INHIBITORS
9.6.1. Overview
9.6.2. Viral Uncoatings Inhibitors Market Forecast and Analysis
9.6.3. Rimantadine Market
9.6.3.1. Overview
9.6.3.2. Rimantadine Market Forecast and Analysis
9.7. IMMUNOMODULATORS
9.7.1. Overview
9.7.2. Immunomodulators Market Forecast and Analysis
9.7.3. Inosine Market
9.7.3.1. Overview
9.7.3.2. Inosine Market Forecast and Analysis
10. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - VACCINE TYPE
10.1. OVERVIEW
10.2. VACCINE TYPE MARKET FORECASTS AND ANALYSIS
10.3. QUADRIVALENT, TRIVALENT ,OTHERS
10.3.1. Overview
10.3.2. Quadrivalent, Trivalent ,Others Market Forecast and Analysis
11. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTES OF ADMINISTRATION
11.1. OVERVIEW
11.2. ROUTES OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
11.3. ORAL, PARENTERAL, OTHERS
11.3.1. Overview
11.3.2. Oral, Parenteral, Others Market Forecast and Analysis
12. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USERS
12.1. OVERVIEW
12.2. END USERS MARKET FORECASTS AND ANALYSIS
12.3. HOSPITALS, CLINICS, SPECIALTY CLINICS, OTHERS
12.3.1. Overview
12.3.2. Hospitals, Clinics, Specialty Clinics, Others Market Forecast and Analysis
13. INFLUENZA ANTIVIRAL DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
13.1. NORTH AMERICA
13.1.1 North America Influenza Antiviral Drugs Market Overview
13.1.2 North America Influenza Antiviral Drugs Market Forecasts and Analysis
13.1.3 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.1.4 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.1.5 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.1.6 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.1.7 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.1.8 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.1.9 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.1.9.1 United States Influenza Antiviral Drugs Market
13.1.9.1.1 United States Influenza Antiviral Drugs Market by Type
13.1.9.1.2 United States Influenza Antiviral Drugs Market by Treatment Type
13.1.9.1.3 United States Influenza Antiviral Drugs Market by Mechanism of Action
13.1.9.1.4 United States Influenza Antiviral Drugs Market by Vaccine Type
13.1.9.1.5 United States Influenza Antiviral Drugs Market by Routes of Administration
13.1.9.1.6 United States Influenza Antiviral Drugs Market by End Users
13.1.9.2 Canada Influenza Antiviral Drugs Market
13.1.9.2.1 Canada Influenza Antiviral Drugs Market by Type
13.1.9.2.2 Canada Influenza Antiviral Drugs Market by Treatment Type
13.1.9.2.3 Canada Influenza Antiviral Drugs Market by Mechanism of Action
13.1.9.2.4 Canada Influenza Antiviral Drugs Market by Vaccine Type
13.1.9.2.5 Canada Influenza Antiviral Drugs Market by Routes of Administration
13.1.9.2.6 Canada Influenza Antiviral Drugs Market by End Users
13.1.9.3 Mexico Influenza Antiviral Drugs Market
13.1.9.3.1 Mexico Influenza Antiviral Drugs Market by Type
13.1.9.3.2 Mexico Influenza Antiviral Drugs Market by Treatment Type
13.1.9.3.3 Mexico Influenza Antiviral Drugs Market by Mechanism of Action
13.1.9.3.4 Mexico Influenza Antiviral Drugs Market by Vaccine Type
13.1.9.3.5 Mexico Influenza Antiviral Drugs Market by Routes of Administration
13.1.9.3.6 Mexico Influenza Antiviral Drugs Market by End Users
13.2. EUROPE
13.2.1 Europe Influenza Antiviral Drugs Market Overview
13.2.2 Europe Influenza Antiviral Drugs Market Forecasts and Analysis
13.2.3 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.2.4 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.2.5 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.2.6 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.2.7 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.2.8 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.2.9 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.2.9.1 Germany Influenza Antiviral Drugs Market
13.2.9.1.1 Germany Influenza Antiviral Drugs Market by Type
13.2.9.1.2 Germany Influenza Antiviral Drugs Market by Treatment Type
13.2.9.1.3 Germany Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.1.4 Germany Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.1.5 Germany Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.1.6 Germany Influenza Antiviral Drugs Market by End Users
13.2.9.2 France Influenza Antiviral Drugs Market
13.2.9.2.1 France Influenza Antiviral Drugs Market by Type
13.2.9.2.2 France Influenza Antiviral Drugs Market by Treatment Type
13.2.9.2.3 France Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.2.4 France Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.2.5 France Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.2.6 France Influenza Antiviral Drugs Market by End Users
13.2.9.3 Italy Influenza Antiviral Drugs Market
13.2.9.3.1 Italy Influenza Antiviral Drugs Market by Type
13.2.9.3.2 Italy Influenza Antiviral Drugs Market by Treatment Type
13.2.9.3.3 Italy Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.3.4 Italy Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.3.5 Italy Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.3.6 Italy Influenza Antiviral Drugs Market by End Users
13.2.9.4 Spain Influenza Antiviral Drugs Market
13.2.9.4.1 Spain Influenza Antiviral Drugs Market by Type
13.2.9.4.2 Spain Influenza Antiviral Drugs Market by Treatment Type
13.2.9.4.3 Spain Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.4.4 Spain Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.4.5 Spain Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.4.6 Spain Influenza Antiviral Drugs Market by End Users
13.2.9.5 United Kingdom Influenza Antiviral Drugs Market
13.2.9.5.1 United Kingdom Influenza Antiviral Drugs Market by Type
13.2.9.5.2 United Kingdom Influenza Antiviral Drugs Market by Treatment Type
13.2.9.5.3 United Kingdom Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.5.4 United Kingdom Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.5.5 United Kingdom Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.5.6 United Kingdom Influenza Antiviral Drugs Market by End Users
13.2.9.6 Rest of Europe Influenza Antiviral Drugs Market
13.2.9.6.1 Rest of Europe Influenza Antiviral Drugs Market by Type
13.2.9.6.2 Rest of Europe Influenza Antiviral Drugs Market by Treatment Type
13.2.9.6.3 Rest of Europe Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.6.4 Rest of Europe Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.6.5 Rest of Europe Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.6.6 Rest of Europe Influenza Antiviral Drugs Market by End Users
13.3. ASIA-PACIFIC
13.3.1 Asia-Pacific Influenza Antiviral Drugs Market Overview
13.3.2 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis
13.3.3 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.3.4 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.3.5 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.3.6 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.3.7 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.3.8 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.3.9 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.3.9.1 Australia Influenza Antiviral Drugs Market
13.3.9.1.1 Australia Influenza Antiviral Drugs Market by Type
13.3.9.1.2 Australia Influenza Antiviral Drugs Market by Treatment Type
13.3.9.1.3 Australia Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.1.4 Australia Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.1.5 Australia Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.1.6 Australia Influenza Antiviral Drugs Market by End Users
13.3.9.2 China Influenza Antiviral Drugs Market
13.3.9.2.1 China Influenza Antiviral Drugs Market by Type
13.3.9.2.2 China Influenza Antiviral Drugs Market by Treatment Type
13.3.9.2.3 China Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.2.4 China Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.2.5 China Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.2.6 China Influenza Antiviral Drugs Market by End Users
13.3.9.3 India Influenza Antiviral Drugs Market
13.3.9.3.1 India Influenza Antiviral Drugs Market by Type
13.3.9.3.2 India Influenza Antiviral Drugs Market by Treatment Type
13.3.9.3.3 India Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.3.4 India Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.3.5 India Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.3.6 India Influenza Antiviral Drugs Market by End Users
13.3.9.4 Japan Influenza Antiviral Drugs Market
13.3.9.4.1 Japan Influenza Antiviral Drugs Market by Type
13.3.9.4.2 Japan Influenza Antiviral Drugs Market by Treatment Type
13.3.9.4.3 Japan Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.4.4 Japan Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.4.5 Japan Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.4.6 Japan Influenza Antiviral Drugs Market by End Users
13.3.9.5 South Korea Influenza Antiviral Drugs Market
13.3.9.5.1 South Korea Influenza Antiviral Drugs Market by Type
13.3.9.5.2 South Korea Influenza Antiviral Drugs Market by Treatment Type
13.3.9.5.3 South Korea Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.5.4 South Korea Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.5.5 South Korea Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.5.6 South Korea Influenza Antiviral Drugs Market by End Users
13.3.9.6 Rest of Asia-Pacific Influenza Antiviral Drugs Market
13.3.9.6.1 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Type
13.3.9.6.2 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Treatment Type
13.3.9.6.3 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.6.4 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.6.5 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.6.6 Rest of Asia-Pacific Influenza Antiviral Drugs Market by End Users
13.4. MIDDLE EAST AND AFRICA
13.4.1 Middle East and Africa Influenza Antiviral Drugs Market Overview
13.4.2 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis
13.4.3 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.4.4 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.4.5 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.4.6 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.4.7 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.4.8 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.4.9 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.4.9.1 South Africa Influenza Antiviral Drugs Market
13.4.9.1.1 South Africa Influenza Antiviral Drugs Market by Type
13.4.9.1.2 South Africa Influenza Antiviral Drugs Market by Treatment Type
13.4.9.1.3 South Africa Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.1.4 South Africa Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.1.5 South Africa Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.1.6 South Africa Influenza Antiviral Drugs Market by End Users
13.4.9.2 Saudi Arabia Influenza Antiviral Drugs Market
13.4.9.2.1 Saudi Arabia Influenza Antiviral Drugs Market by Type
13.4.9.2.2 Saudi Arabia Influenza Antiviral Drugs Market by Treatment Type
13.4.9.2.3 Saudi Arabia Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.2.4 Saudi Arabia Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.2.5 Saudi Arabia Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.2.6 Saudi Arabia Influenza Antiviral Drugs Market by End Users
13.4.9.3 U.A.E Influenza Antiviral Drugs Market
13.4.9.3.1 U.A.E Influenza Antiviral Drugs Market by Type
13.4.9.3.2 U.A.E Influenza Antiviral Drugs Market by Treatment Type
13.4.9.3.3 U.A.E Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.3.4 U.A.E Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.3.5 U.A.E Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.3.6 U.A.E Influenza Antiviral Drugs Market by End Users
13.4.9.4 Rest of Middle East and Africa Influenza Antiviral Drugs Market
13.4.9.4.1 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Type
13.4.9.4.2 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Treatment Type
13.4.9.4.3 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.4.4 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.4.5 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.4.6 Rest of Middle East and Africa Influenza Antiviral Drugs Market by End Users
13.5. SOUTH AND CENTRAL AMERICA
13.5.1 South and Central America Influenza Antiviral Drugs Market Overview
13.5.2 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis
13.5.3 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.5.4 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.5.5 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.5.6 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.5.7 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.5.8 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.5.9 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.5.9.1 Brazil Influenza Antiviral Drugs Market
13.5.9.1.1 Brazil Influenza Antiviral Drugs Market by Type
13.5.9.1.2 Brazil Influenza Antiviral Drugs Market by Treatment Type
13.5.9.1.3 Brazil Influenza Antiviral Drugs Market by Mechanism of Action
13.5.9.1.4 Brazil Influenza Antiviral Drugs Market by Vaccine Type
13.5.9.1.5 Brazil Influenza Antiviral Drugs Market by Routes of Administration
13.5.9.1.6 Brazil Influenza Antiviral Drugs Market by End Users
13.5.9.2 Argentina Influenza Antiviral Drugs Market
13.5.9.2.1 Argentina Influenza Antiviral Drugs Market by Type
13.5.9.2.2 Argentina Influenza Antiviral Drugs Market by Treatment Type
13.5.9.2.3 Argentina Influenza Antiviral Drugs Market by Mechanism of Action
13.5.9.2.4 Argentina Influenza Antiviral Drugs Market by Vaccine Type
13.5.9.2.5 Argentina Influenza Antiviral Drugs Market by Routes of Administration
13.5.9.2.6 Argentina Influenza Antiviral Drugs Market by End Users
13.5.9.3 Rest of South and Central America Influenza Antiviral Drugs Market
13.5.9.3.1 Rest of South and Central America Influenza Antiviral Drugs Market by Type
13.5.9.3.2 Rest of South and Central America Influenza Antiviral Drugs Market by Treatment Type
13.5.9.3.3 Rest of South and Central America Influenza Antiviral Drugs Market by Mechanism of Action
13.5.9.3.4 Rest of South and Central America Influenza Antiviral Drugs Market by Vaccine Type
13.5.9.3.5 Rest of South and Central America Influenza Antiviral Drugs Market by Routes of Administration
13.5.9.3.6 Rest of South and Central America Influenza Antiviral Drugs Market by End Users
14. INDUSTRY LANDSCAPE
14.1. MERGERS AND ACQUISITIONS
14.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
14.3. NEW PRODUCT LAUNCHES
14.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
15. INFLUENZA ANTIVIRAL DRUGS MARKET, KEY COMPANY PROFILES
15.1. SUN PHARMACEUTICAL INDUSTRIES LTD
15.1.1. Key Facts
15.1.2. Business Description
15.1.3. Products and Services
15.1.4. Financial Overview
15.1.5. SWOT Analysis
15.1.6. Key Developments
15.2. ADMA BIOLOGICS, INC
15.2.1. Key Facts
15.2.2. Business Description
15.2.3. Products and Services
15.2.4. Financial Overview
15.2.5. SWOT Analysis
15.2.6. Key Developments
15.3. SHIONOGI INC
15.3.1. Key Facts
15.3.2. Business Description
15.3.3. Products and Services
15.3.4. Financial Overview
15.3.5. SWOT Analysis
15.3.6. Key Developments
15.4. F. HOFFMANN-LA ROCHE LTD
15.4.1. Key Facts
15.4.2. Business Description
15.4.3. Products and Services
15.4.4. Financial Overview
15.4.5. SWOT Analysis
15.4.6. Key Developments
15.5. CIPLA INC
15.5.1. Key Facts
15.5.2. Business Description
15.5.3. Products and Services
15.5.4. Financial Overview
15.5.5. SWOT Analysis
15.5.6. Key Developments
15.6. GLAXOSMITHKLINE PLC
15.6.1. Key Facts
15.6.2. Business Description
15.6.3. Products and Services
15.6.4. Financial Overview
15.6.5. SWOT Analysis
15.6.6. Key Developments
15.7. TEVA PHARMACEUTICAL INDUSTRIES LTD
15.7.1. Key Facts
15.7.2. Business Description
15.7.3. Products and Services
15.7.4. Financial Overview
15.7.5. SWOT Analysis
15.7.6. Key Developments
15.8. NOVARTIS AG
15.8.1. Key Facts
15.8.2. Business Description
15.8.3. Products and Services
15.8.4. Financial Overview
15.8.5. SWOT Analysis
15.8.6. Key Developments
15.9. SANOFI
15.9.1. Key Facts
15.9.2. Business Description
15.9.3. Products and Services
15.9.4. Financial Overview
15.9.5. SWOT Analysis
15.9.6. Key Developments
15.10. ASTRAZENECA
15.10.1. Key Facts
15.10.2. Business Description
15.10.3. Products and Services
15.10.4. Financial Overview
15.10.5. SWOT Analysis
15.10.6. Key Developments
16. APPENDIX
16.1. ABOUT THE INSIGHT PARTNERS
16.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Influenza Antiviral Drugs Market - By Type
1.3.2 Influenza Antiviral Drugs Market - By Treatment Type
1.3.3 Influenza Antiviral Drugs Market - By Mechanism of Action
1.3.4 Influenza Antiviral Drugs Market - By Vaccine Type
1.3.5 Influenza Antiviral Drugs Market - By Routes of Administration
1.3.6 Influenza Antiviral Drugs Market - By End Users
1.3.7 Influenza Antiviral Drugs Market - By Region
1.3.7.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. INFLUENZA ANTIVIRAL DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. INFLUENZA ANTIVIRAL DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. INFLUENZA ANTIVIRAL DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. INFLUENZA ANTIVIRAL DRUGS - GLOBAL MARKET OVERVIEW
6.2. INFLUENZA ANTIVIRAL DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. INFLUENZA A, INFLUENZA B, INFLUENZA C
7.3.1. Overview
7.3.2. Influenza A, Influenza B, Influenza C Market Forecast and Analysis
8. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT TYPE
8.1. OVERVIEW
8.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
8.3. MEDICATION, CHEMOPROPHYLAXIS, OTHERS
8.3.1. Overview
8.3.2. Medication, Chemoprophylaxis, Others Market Forecast and Analysis
9. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - MECHANISM OF ACTION
9.1. OVERVIEW
9.2. MECHANISM OF ACTION MARKET FORECASTS AND ANALYSIS
9.3. CAP- DEPENDENT ENDONUCLEASE INHIBITOR
9.3.1. Overview
9.3.2. Cap- dependent endonuclease inhibitor Market Forecast and Analysis
9.3.3. Daloxavir Market
9.3.3.1. Overview
9.3.3.2. Daloxavir Market Forecast and Analysis
9.4. NURAMINIDASE INHIBITOR
9.4.1. Overview
9.4.2. Nuraminidase Inhibitor Market Forecast and Analysis
9.4.3. Oseltamivir Market
9.4.3.1. Overview
9.4.3.2. Oseltamivir Market Forecast and Analysis
9.4.4. Zanamivir Market
9.4.4.1. Overview
9.4.4.2. Zanamivir Market Forecast and Analysis
9.4.5. Peramivir Market
9.4.5.1. Overview
9.4.5.2. Peramivir Market Forecast and Analysis
9.5. MATRIX-2 PROTEIN INHIBITOR
9.5.1. Overview
9.5.2. Matrix-2 Protein Inhibitor Market Forecast and Analysis
9.5.3. Amantadine Market
9.5.3.1. Overview
9.5.3.2. Amantadine Market Forecast and Analysis
9.6. VIRAL UNCOATINGS INHIBITORS
9.6.1. Overview
9.6.2. Viral Uncoatings Inhibitors Market Forecast and Analysis
9.6.3. Rimantadine Market
9.6.3.1. Overview
9.6.3.2. Rimantadine Market Forecast and Analysis
9.7. IMMUNOMODULATORS
9.7.1. Overview
9.7.2. Immunomodulators Market Forecast and Analysis
9.7.3. Inosine Market
9.7.3.1. Overview
9.7.3.2. Inosine Market Forecast and Analysis
10. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - VACCINE TYPE
10.1. OVERVIEW
10.2. VACCINE TYPE MARKET FORECASTS AND ANALYSIS
10.3. QUADRIVALENT, TRIVALENT ,OTHERS
10.3.1. Overview
10.3.2. Quadrivalent, Trivalent ,Others Market Forecast and Analysis
11. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTES OF ADMINISTRATION
11.1. OVERVIEW
11.2. ROUTES OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
11.3. ORAL, PARENTERAL, OTHERS
11.3.1. Overview
11.3.2. Oral, Parenteral, Others Market Forecast and Analysis
12. INFLUENZA ANTIVIRAL DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USERS
12.1. OVERVIEW
12.2. END USERS MARKET FORECASTS AND ANALYSIS
12.3. HOSPITALS, CLINICS, SPECIALTY CLINICS, OTHERS
12.3.1. Overview
12.3.2. Hospitals, Clinics, Specialty Clinics, Others Market Forecast and Analysis
13. INFLUENZA ANTIVIRAL DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
13.1. NORTH AMERICA
13.1.1 North America Influenza Antiviral Drugs Market Overview
13.1.2 North America Influenza Antiviral Drugs Market Forecasts and Analysis
13.1.3 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.1.4 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.1.5 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.1.6 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.1.7 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.1.8 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.1.9 North America Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.1.9.1 United States Influenza Antiviral Drugs Market
13.1.9.1.1 United States Influenza Antiviral Drugs Market by Type
13.1.9.1.2 United States Influenza Antiviral Drugs Market by Treatment Type
13.1.9.1.3 United States Influenza Antiviral Drugs Market by Mechanism of Action
13.1.9.1.4 United States Influenza Antiviral Drugs Market by Vaccine Type
13.1.9.1.5 United States Influenza Antiviral Drugs Market by Routes of Administration
13.1.9.1.6 United States Influenza Antiviral Drugs Market by End Users
13.1.9.2 Canada Influenza Antiviral Drugs Market
13.1.9.2.1 Canada Influenza Antiviral Drugs Market by Type
13.1.9.2.2 Canada Influenza Antiviral Drugs Market by Treatment Type
13.1.9.2.3 Canada Influenza Antiviral Drugs Market by Mechanism of Action
13.1.9.2.4 Canada Influenza Antiviral Drugs Market by Vaccine Type
13.1.9.2.5 Canada Influenza Antiviral Drugs Market by Routes of Administration
13.1.9.2.6 Canada Influenza Antiviral Drugs Market by End Users
13.1.9.3 Mexico Influenza Antiviral Drugs Market
13.1.9.3.1 Mexico Influenza Antiviral Drugs Market by Type
13.1.9.3.2 Mexico Influenza Antiviral Drugs Market by Treatment Type
13.1.9.3.3 Mexico Influenza Antiviral Drugs Market by Mechanism of Action
13.1.9.3.4 Mexico Influenza Antiviral Drugs Market by Vaccine Type
13.1.9.3.5 Mexico Influenza Antiviral Drugs Market by Routes of Administration
13.1.9.3.6 Mexico Influenza Antiviral Drugs Market by End Users
13.2. EUROPE
13.2.1 Europe Influenza Antiviral Drugs Market Overview
13.2.2 Europe Influenza Antiviral Drugs Market Forecasts and Analysis
13.2.3 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.2.4 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.2.5 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.2.6 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.2.7 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.2.8 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.2.9 Europe Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.2.9.1 Germany Influenza Antiviral Drugs Market
13.2.9.1.1 Germany Influenza Antiviral Drugs Market by Type
13.2.9.1.2 Germany Influenza Antiviral Drugs Market by Treatment Type
13.2.9.1.3 Germany Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.1.4 Germany Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.1.5 Germany Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.1.6 Germany Influenza Antiviral Drugs Market by End Users
13.2.9.2 France Influenza Antiviral Drugs Market
13.2.9.2.1 France Influenza Antiviral Drugs Market by Type
13.2.9.2.2 France Influenza Antiviral Drugs Market by Treatment Type
13.2.9.2.3 France Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.2.4 France Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.2.5 France Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.2.6 France Influenza Antiviral Drugs Market by End Users
13.2.9.3 Italy Influenza Antiviral Drugs Market
13.2.9.3.1 Italy Influenza Antiviral Drugs Market by Type
13.2.9.3.2 Italy Influenza Antiviral Drugs Market by Treatment Type
13.2.9.3.3 Italy Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.3.4 Italy Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.3.5 Italy Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.3.6 Italy Influenza Antiviral Drugs Market by End Users
13.2.9.4 Spain Influenza Antiviral Drugs Market
13.2.9.4.1 Spain Influenza Antiviral Drugs Market by Type
13.2.9.4.2 Spain Influenza Antiviral Drugs Market by Treatment Type
13.2.9.4.3 Spain Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.4.4 Spain Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.4.5 Spain Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.4.6 Spain Influenza Antiviral Drugs Market by End Users
13.2.9.5 United Kingdom Influenza Antiviral Drugs Market
13.2.9.5.1 United Kingdom Influenza Antiviral Drugs Market by Type
13.2.9.5.2 United Kingdom Influenza Antiviral Drugs Market by Treatment Type
13.2.9.5.3 United Kingdom Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.5.4 United Kingdom Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.5.5 United Kingdom Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.5.6 United Kingdom Influenza Antiviral Drugs Market by End Users
13.2.9.6 Rest of Europe Influenza Antiviral Drugs Market
13.2.9.6.1 Rest of Europe Influenza Antiviral Drugs Market by Type
13.2.9.6.2 Rest of Europe Influenza Antiviral Drugs Market by Treatment Type
13.2.9.6.3 Rest of Europe Influenza Antiviral Drugs Market by Mechanism of Action
13.2.9.6.4 Rest of Europe Influenza Antiviral Drugs Market by Vaccine Type
13.2.9.6.5 Rest of Europe Influenza Antiviral Drugs Market by Routes of Administration
13.2.9.6.6 Rest of Europe Influenza Antiviral Drugs Market by End Users
13.3. ASIA-PACIFIC
13.3.1 Asia-Pacific Influenza Antiviral Drugs Market Overview
13.3.2 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis
13.3.3 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.3.4 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.3.5 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.3.6 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.3.7 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.3.8 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.3.9 Asia-Pacific Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.3.9.1 Australia Influenza Antiviral Drugs Market
13.3.9.1.1 Australia Influenza Antiviral Drugs Market by Type
13.3.9.1.2 Australia Influenza Antiviral Drugs Market by Treatment Type
13.3.9.1.3 Australia Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.1.4 Australia Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.1.5 Australia Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.1.6 Australia Influenza Antiviral Drugs Market by End Users
13.3.9.2 China Influenza Antiviral Drugs Market
13.3.9.2.1 China Influenza Antiviral Drugs Market by Type
13.3.9.2.2 China Influenza Antiviral Drugs Market by Treatment Type
13.3.9.2.3 China Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.2.4 China Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.2.5 China Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.2.6 China Influenza Antiviral Drugs Market by End Users
13.3.9.3 India Influenza Antiviral Drugs Market
13.3.9.3.1 India Influenza Antiviral Drugs Market by Type
13.3.9.3.2 India Influenza Antiviral Drugs Market by Treatment Type
13.3.9.3.3 India Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.3.4 India Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.3.5 India Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.3.6 India Influenza Antiviral Drugs Market by End Users
13.3.9.4 Japan Influenza Antiviral Drugs Market
13.3.9.4.1 Japan Influenza Antiviral Drugs Market by Type
13.3.9.4.2 Japan Influenza Antiviral Drugs Market by Treatment Type
13.3.9.4.3 Japan Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.4.4 Japan Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.4.5 Japan Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.4.6 Japan Influenza Antiviral Drugs Market by End Users
13.3.9.5 South Korea Influenza Antiviral Drugs Market
13.3.9.5.1 South Korea Influenza Antiviral Drugs Market by Type
13.3.9.5.2 South Korea Influenza Antiviral Drugs Market by Treatment Type
13.3.9.5.3 South Korea Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.5.4 South Korea Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.5.5 South Korea Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.5.6 South Korea Influenza Antiviral Drugs Market by End Users
13.3.9.6 Rest of Asia-Pacific Influenza Antiviral Drugs Market
13.3.9.6.1 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Type
13.3.9.6.2 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Treatment Type
13.3.9.6.3 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Mechanism of Action
13.3.9.6.4 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Vaccine Type
13.3.9.6.5 Rest of Asia-Pacific Influenza Antiviral Drugs Market by Routes of Administration
13.3.9.6.6 Rest of Asia-Pacific Influenza Antiviral Drugs Market by End Users
13.4. MIDDLE EAST AND AFRICA
13.4.1 Middle East and Africa Influenza Antiviral Drugs Market Overview
13.4.2 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis
13.4.3 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.4.4 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.4.5 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.4.6 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.4.7 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.4.8 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.4.9 Middle East and Africa Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.4.9.1 South Africa Influenza Antiviral Drugs Market
13.4.9.1.1 South Africa Influenza Antiviral Drugs Market by Type
13.4.9.1.2 South Africa Influenza Antiviral Drugs Market by Treatment Type
13.4.9.1.3 South Africa Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.1.4 South Africa Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.1.5 South Africa Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.1.6 South Africa Influenza Antiviral Drugs Market by End Users
13.4.9.2 Saudi Arabia Influenza Antiviral Drugs Market
13.4.9.2.1 Saudi Arabia Influenza Antiviral Drugs Market by Type
13.4.9.2.2 Saudi Arabia Influenza Antiviral Drugs Market by Treatment Type
13.4.9.2.3 Saudi Arabia Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.2.4 Saudi Arabia Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.2.5 Saudi Arabia Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.2.6 Saudi Arabia Influenza Antiviral Drugs Market by End Users
13.4.9.3 U.A.E Influenza Antiviral Drugs Market
13.4.9.3.1 U.A.E Influenza Antiviral Drugs Market by Type
13.4.9.3.2 U.A.E Influenza Antiviral Drugs Market by Treatment Type
13.4.9.3.3 U.A.E Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.3.4 U.A.E Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.3.5 U.A.E Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.3.6 U.A.E Influenza Antiviral Drugs Market by End Users
13.4.9.4 Rest of Middle East and Africa Influenza Antiviral Drugs Market
13.4.9.4.1 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Type
13.4.9.4.2 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Treatment Type
13.4.9.4.3 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Mechanism of Action
13.4.9.4.4 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Vaccine Type
13.4.9.4.5 Rest of Middle East and Africa Influenza Antiviral Drugs Market by Routes of Administration
13.4.9.4.6 Rest of Middle East and Africa Influenza Antiviral Drugs Market by End Users
13.5. SOUTH AND CENTRAL AMERICA
13.5.1 South and Central America Influenza Antiviral Drugs Market Overview
13.5.2 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis
13.5.3 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Type
13.5.4 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Treatment Type
13.5.5 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Mechanism of Action
13.5.6 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Vaccine Type
13.5.7 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Routes of Administration
13.5.8 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By End Users
13.5.9 South and Central America Influenza Antiviral Drugs Market Forecasts and Analysis - By Countries
13.5.9.1 Brazil Influenza Antiviral Drugs Market
13.5.9.1.1 Brazil Influenza Antiviral Drugs Market by Type
13.5.9.1.2 Brazil Influenza Antiviral Drugs Market by Treatment Type
13.5.9.1.3 Brazil Influenza Antiviral Drugs Market by Mechanism of Action
13.5.9.1.4 Brazil Influenza Antiviral Drugs Market by Vaccine Type
13.5.9.1.5 Brazil Influenza Antiviral Drugs Market by Routes of Administration
13.5.9.1.6 Brazil Influenza Antiviral Drugs Market by End Users
13.5.9.2 Argentina Influenza Antiviral Drugs Market
13.5.9.2.1 Argentina Influenza Antiviral Drugs Market by Type
13.5.9.2.2 Argentina Influenza Antiviral Drugs Market by Treatment Type
13.5.9.2.3 Argentina Influenza Antiviral Drugs Market by Mechanism of Action
13.5.9.2.4 Argentina Influenza Antiviral Drugs Market by Vaccine Type
13.5.9.2.5 Argentina Influenza Antiviral Drugs Market by Routes of Administration
13.5.9.2.6 Argentina Influenza Antiviral Drugs Market by End Users
13.5.9.3 Rest of South and Central America Influenza Antiviral Drugs Market
13.5.9.3.1 Rest of South and Central America Influenza Antiviral Drugs Market by Type
13.5.9.3.2 Rest of South and Central America Influenza Antiviral Drugs Market by Treatment Type
13.5.9.3.3 Rest of South and Central America Influenza Antiviral Drugs Market by Mechanism of Action
13.5.9.3.4 Rest of South and Central America Influenza Antiviral Drugs Market by Vaccine Type
13.5.9.3.5 Rest of South and Central America Influenza Antiviral Drugs Market by Routes of Administration
13.5.9.3.6 Rest of South and Central America Influenza Antiviral Drugs Market by End Users
14. INDUSTRY LANDSCAPE
14.1. MERGERS AND ACQUISITIONS
14.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
14.3. NEW PRODUCT LAUNCHES
14.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
15. INFLUENZA ANTIVIRAL DRUGS MARKET, KEY COMPANY PROFILES
15.1. SUN PHARMACEUTICAL INDUSTRIES LTD
15.1.1. Key Facts
15.1.2. Business Description
15.1.3. Products and Services
15.1.4. Financial Overview
15.1.5. SWOT Analysis
15.1.6. Key Developments
15.2. ADMA BIOLOGICS, INC
15.2.1. Key Facts
15.2.2. Business Description
15.2.3. Products and Services
15.2.4. Financial Overview
15.2.5. SWOT Analysis
15.2.6. Key Developments
15.3. SHIONOGI INC
15.3.1. Key Facts
15.3.2. Business Description
15.3.3. Products and Services
15.3.4. Financial Overview
15.3.5. SWOT Analysis
15.3.6. Key Developments
15.4. F. HOFFMANN-LA ROCHE LTD
15.4.1. Key Facts
15.4.2. Business Description
15.4.3. Products and Services
15.4.4. Financial Overview
15.4.5. SWOT Analysis
15.4.6. Key Developments
15.5. CIPLA INC
15.5.1. Key Facts
15.5.2. Business Description
15.5.3. Products and Services
15.5.4. Financial Overview
15.5.5. SWOT Analysis
15.5.6. Key Developments
15.6. GLAXOSMITHKLINE PLC
15.6.1. Key Facts
15.6.2. Business Description
15.6.3. Products and Services
15.6.4. Financial Overview
15.6.5. SWOT Analysis
15.6.6. Key Developments
15.7. TEVA PHARMACEUTICAL INDUSTRIES LTD
15.7.1. Key Facts
15.7.2. Business Description
15.7.3. Products and Services
15.7.4. Financial Overview
15.7.5. SWOT Analysis
15.7.6. Key Developments
15.8. NOVARTIS AG
15.8.1. Key Facts
15.8.2. Business Description
15.8.3. Products and Services
15.8.4. Financial Overview
15.8.5. SWOT Analysis
15.8.6. Key Developments
15.9. SANOFI
15.9.1. Key Facts
15.9.2. Business Description
15.9.3. Products and Services
15.9.4. Financial Overview
15.9.5. SWOT Analysis
15.9.6. Key Developments
15.10. ASTRAZENECA
15.10.1. Key Facts
15.10.2. Business Description
15.10.3. Products and Services
15.10.4. Financial Overview
15.10.5. SWOT Analysis
15.10.6. Key Developments
16. APPENDIX
16.1. ABOUT THE INSIGHT PARTNERS
16.2. GLOSSARY OF TERMS
The List of Companies
1. Sun Pharmaceutical Industries Ltd
2. ADMA Biologics, Inc
3. Shionogi Inc
4. F. Hoffmann-La Roche Ltd
5. Cipla Inc
6. GlaxoSmithKline Plc
7. Teva Pharmaceutical Industries Ltd
8. Novartis AG
9. Sanofi
10. AstraZeneca
1. Sun Pharmaceutical Industries Ltd
2. ADMA Biologics, Inc
3. Shionogi Inc
4. F. Hoffmann-La Roche Ltd
5. Cipla Inc
6. GlaxoSmithKline Plc
7. Teva Pharmaceutical Industries Ltd
8. Novartis AG
9. Sanofi
10. AstraZeneca
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For